Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
50 hedge funds and large institutions have $204M invested in Constellation Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more funds holding
Funds holding: 44 → 50 (+6)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
9% less capital invested
Capital invested by funds: $225M → $204M (-$21M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.39M |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$1.34M |
| 4 |
BlackRock
New York
|
+$1.05M |
| 5 |
State Street
Boston,
Massachusetts
|
+$839K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.22M |
| 2 |
First Eagle Investment Management
New York
|
-$1.07M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$897K |
| 4 |
DM
Deerfield Management
New York
|
-$777K |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$678K |
CNST Hedge Fund Activity: Q2 2019 in Review
50 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q2 2019, worth a combined $204M — down 9.3% from $225M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CNST positions and 5 closed out — a net gain of 7 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $3.9M. The largest seller was Fidelity Investments, cutting an estimated $2.22M.
- 50 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q2 2019, up from 44 in Q1 2019.
- Funds reported $204M of Constellation Pharmaceuticals, Inc. stock for Q2 2019, down 9.3% quarter-over-quarter.
- 12 funds opened new Constellation Pharmaceuticals, Inc. positions in Q2 2019 and 5 closed out, a net change of +7 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q2 2019 was T. Rowe Price Associates, an estimated $3.9M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q2 2019 was Fidelity Investments, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2019.